within Pharmacolibrary.Drugs.N_NervousSystem.N02C_AntimigrainePreparations.N02CX06_Oxetorone;

model Oxetorone
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.3,
    Cl = 9.999999999999999e-06,
    adminDuration = 600,
    adminMass = 60 / 1000000,
    adminCount = 1,
    Vd = 0.006,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.0005,
    Tlag = 600);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Oxetorone</td></tr><tr><td>ATC code:</td><td>N02CX06</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>60</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>6</td><td>L</td></tr>
    <tr><td>clearance:</td><td>600</td><td>mL/min</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Oxetorone is a serotonin antagonist with antihistaminic and antiserotonergic properties, previously used for the prophylactic treatment of migraine. The drug is not approved in many countries today due to its adverse effect profile and lack of modern clinical data.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for oral administration in healthy adults. No published dedicated pharmacokinetic studies or peer-reviewed sources were found for oxetorone.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N02CX06 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Oxetorone;
